Ovation.io Completes $21.5 million Financing to Contribute to the Promise of Precision Medicine

Ovation.io Completes $21.5 million Financing to Contribute to the Promise of Precision Medicine  

By David Shaw

As a founding investor and board member of Ovation, I’m pleased to share that we recently completed a Series B financing round with investments by Black Point Group, SignalFire, Madrona Venture Group, Borealis Ventures, and StageDotO Ventures.  

The company’s announcement, includes this statement by CEO/founder Barry Wark: 

“In the last twelve months, Ovation.io has more than doubled our revenue, grown our patient volume seventy-five fold, and established a rapidly expanding life science business that compliments our existing lab software business. We’ve had the opportunity to make significant contributions to the availability of infectious disease testing capacity in the United States and world wide. Insights from our network of labs have helped drive public policy, and public and private research into the mechanisms, diagnosis, and treatments for COVID-19.”

I’m proud to work with the amazing Ovation team on this  game-changing venture.  Among the company’s remarkable accomplishments in 2020 has been it’s significant contributions to COVID testing in the United States and beyond. 

 The company’s press release can be read HERE